MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of securities
$108,991K
Proceeds from issuance of
common stock under...
$156K
Proceeds from exercise of
stock options
$58K
Net cash provided by
investing activities
$35,224K
Net cash provided by
financing activities
$214K
Canceled cashflow
$73,767K
Net increase
(decrease) in cash, cash...
-$15,258K
Canceled cashflow
$35,438K
Stock-based compensation
$6,844K
Amortization of operating
lease right-of-use...
$4,712K
Depreciation
$1,753K
Accrued expenses and
other liabilities
$629K
Prepaid expenses and
other assets
-$544K
Purchases of securities
$72,490K
Purchases of property and
equipment
$1,277K
Net cash used in
operating activities
-$50,696K
Canceled cashflow
$14,482K
Net loss
-$59,001K
Operating lease
liabilities
-$4,688K
Amortization (accretion) of
premiums (discounts) on...
$1,420K
Accounts payable
-$69K
Back
Back
Cash Flow
source: myfinsight.com
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)